These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34718844)

  • 1. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
    Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
    Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
    Berz AM; Santana JG; Iseke S; Gross M; Pekurovsky V; Laage Gaupp F; Savic LJ; Borde T; Gottwald LA; Boustani AM; Gebauer B; Lin M; Zhang X; Schlachter T; Madoff DC; Chapiro J
    J Vasc Interv Radiol; 2022 Jul; 33(7):764-774.e4. PubMed ID: 35346859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?
    Savic LJ; Doemel LA; Schobert IT; Montgomery RR; Joshi N; Walsh JJ; Santana J; Pekurovsky V; Zhang X; Lin M; Adam L; Boustani A; Duncan J; Leng L; Bucala RJ; Goldberg SN; Hyder F; Coman D; Chapiro J
    Radiology; 2020 Sep; 296(3):575-583. PubMed ID: 32633675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 5. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
    van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
    Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.
    Gaba RC; Khabbaz RC; Muchiri RN; Morrison JD; Elkhadragy L; Totura WM; Samuelson JP; Whiteley HE; Deaton RL; Nguyen PL; Sverdlov M; Johnson JJ; van Breemen RB; Lokken RP
    Drug Deliv Transl Res; 2022 May; 12(5):1105-1117. PubMed ID: 33861419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.
    Savic LJ; Schobert IT; Peters D; Walsh JJ; Laage-Gaupp FM; Hamm CA; Tritz N; Doemel LA; Lin M; Sinusas A; Schlachter T; Duncan JS; Hyder F; Coman D; Chapiro J
    Clin Cancer Res; 2020 Jan; 26(2):428-438. PubMed ID: 31582517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment.
    Borde T; Laage Gaupp F; Geschwind JF; Savic LJ; Miszczuk M; Rexha I; Adam L; Walsh JJ; Huber S; Duncan JS; Peters DC; Sinusas A; Schlachter T; Gebauer B; Hyder F; Coman D; van Breugel JMM; Chapiro J
    J Vasc Interv Radiol; 2020 Oct; 31(10):1706-1716.e1. PubMed ID: 32684417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model.
    Kim D; Lee JH; Moon H; Seo M; Han H; Yoo H; Seo H; Lee J; Hong S; Kim P; Lee HJ; Chung JW; Kim H
    Theranostics; 2021; 11(1):79-92. PubMed ID: 33391462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.
    Elkhadragy L; Khabbaz RC; Muchiri RN; Totura WM; Samuelson JP; Whiteley HE; van Breemen RB; Lokken RP; Gaba RC
    J Vasc Interv Radiol; 2022 Oct; 33(10):1213-1221.e5. PubMed ID: 35850455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
    Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
    Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
    Liu X; Xie Y; Qi X; Xu K
    J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
    Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
    Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.